Jun 16, 2020
MDA's Annual Summer Camp for Children with Neuromuscular Diseases Launches Virtually for 65th Session
Jun 11, 2020
Verge Genomics to advance its inhibitors of PIKfyve for the treatment of ALS and COVID-19
Jun 09, 2020
The ALS Association, I AM ALS Award BrainStorm Cell Therapeutics $500,000 for ALS Biomarker Study
May 26, 2020
CytRx Corporation Highlights Orphazyme's Receipt of FDA Fast Track Designation for the Development of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)
May 13, 2020
Answer ALS is Proud to Announce the Release of New In-Depth Biological and Clinical Datasets to Aid ALS Research
May 12, 2020
Alpha Cognition Inc. Announces Granted EU Patents and Orphan Drug Designation for Its Progranulin Platform
Apr 29, 2020
CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Orphazyme A/S in Niemann-Pick Disease
Apr 14, 2020
Alpha Cognition Inc. Name Change
Apr 09, 2020
Seneca Biopharma Announces Results of Meeting with FDA Regarding the Design of Phase 3 Trial for NSI-566 in ALS
Mar 31, 2020
Muscular Dystrophy Association to Host MDA Frontline COVID-19 Response with Dr. Barry Byrne, a Facebook Live Q&A on Protecting Neuromuscular Disease Community in Midst of COVID-19 Pandemic
Feb 06, 2020
NeuroSense Therapeutics Receives Orphan Drug Designation for Amyotrophic Lateral Sclerosis (ALS) Drug, and Announces Initiation of Two Clinical Studies in ALS
Feb 04, 2020
CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Licensee Orphazyme A/S
Jan 24, 2020
Clene Nanomedicine Announces Formal Acceptance of CNM-Au8 for HEALEY ALS Platform Trial as Center Receives FDA Approval to Proceed
Jan 22, 2020
Biohaven's Verdiperstat Receives FDA May Proceed Letter To Initiate Trial In Amyotrophic Lateral Sclerosis Conducted By The Healey Center For ALS At Mass General
Jan 21, 2020
Clene Nanomedicine Announces First Patient Dosed in the RESCUE-ALS Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with Lead Nanocatalytic Therapeutic, CNM-Au8
Jan 14, 2020
ALS Association Makes Multi-Year Commitment to HEALEY ALS Platform Trial
Jan 13, 2020
MDA Awards Venture Philanthropy Funding of More Than $1M to AavantiBio to Develop Gene-Targeting Therapy for Friedreich's Ataxia
Jan 06, 2020
Kadimastem Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS
Dec 23, 2019
Kadimastem Announces the Completion of Treatment for Cohort B of Its Phase 1/2a Clinical Trial in ALS Patients
Dec 13, 2019
ITF Pharma Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIGLUTIK® (riluzole) Oral Suspension For The Treatment Of Amyotrophic Lateral Sclerosis (ALS) with a Percutaneous Endoscopic Gastronomy (PEG) Feeding Tube